Ownership history in MYDA Advisors LLC Β· 11 quarters on record
This page tracks every 13F SEC filing in which MYDA Advisors LLC reported a position in ARCUTIS BIOTHERAPEUTICS INC (ARQT). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π MYDA Advisors LLC outperformed the S&P 500 by +46.3% annually on this ARQT position. Timing score: 62% (5/8 decisions correct). Average cost basis: $18.75. Maximum drawdown during holding period: β10.4%.
π₯ Exceptional β beat the S&P 500 by 46.3% per year on this position.
9 quarters analyzed
β
Decent timing β more right than wrong on entries and exits.
5 of 8 add/trim decisions correct
Best entry: $9.30 (2024 Q3) Β· Worst: $29.04 (2025 Q4)
π No drawdown exceeding 20% during the holding period β exceptionally stable.
7 adds Β· 3 trims. Bought during 1 of 2 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 1.47% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size